A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients with Advanced Systemic Mastocytosis
The purpose of this study is to: • to determine the optimal dose of oral CGT9486 in patients with Advanced Systemic Mastocytosis (AdvSM). • to determine the efficacy of CGT9486 at the selected optimal dose in patients with Advanced Systemic Mastocytosis (AdvSM).
Are you Eligible? (Inclusion Criteria)
- Age ≥18 years of age
- Have a form of Advanced Systemic Mastocytosis (including Aggressive Systemic Mastocytosis, Advanced Systemic Mastocytosis with an Associated Hematologic Neoplasm, or Mast Cell Leukemia).
- Measurable disease, per Diagnosis of Systemic Mastocytosis (SM) criteria.